Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
GCNT3
REST API REST API
Homo sapiens
GCNT3 is differentially expressed in 157 experiments: 102 organism parts: trachea, tonsil, ... (100 more);, 105 disease states: normal, colorectal carcinoma, ... (103 more);, 37 cell types 364 cell lines 26 compound treatments and 55 other conditions.
Synonyms C2/4GnT, C2GnT2, C2GnT-M
Orthologs GCNT3 (Danio rerio)   Gcnt3 (Mus musculus)   GCNT3 (Gallus gallus)   GCNT3_BOVIN (Bos taurus)   ENSCING00000013219 (Ciona intestinalis)   Gcnt3 (Rattus norvegicus)   LOC100486342 (Xenopus laevis)   GCNT3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term acetylglucosaminyltransferase activity, membrane, Golgi membrane, Golgi apparatus, metabolic process, membrane fraction, transferase activity, transferring glycosyl groups, N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity, carbohydrate metabolic process, integral to membrane, kidney morphogenesis, intestinal absorption, tissue morphogenesis, beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase activity, protein O-linked glycosylation, immunoglobulin production in mucosal tissue, acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase activity
InterPro Term Glyco_trans_14
UniProt Accession O95395
Search EB-eye ENSG00000140297
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-GEOD-7224, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-MTAB-62, ... (27 experiments)

Factor Value U/D Experiments
SKBR3
2
E-MEXP-440, E-MTAB-62
SNU1
2
E-MTAB-37, E-GEOD-15460
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-MTAB-37, E-GEOD-15460
DU145
2
E-GEOD-17482, E-GEOD-20089
H1437
2
E-MTAB-62, E-GEOD-16194
358 more value(s).


Cell type

studied in E-GEOD-15893, E-GEOD-18811, E-AFMX-5, E-MEXP-1251, E-GEOD-22373, ... (23 experiments)

Factor Value U/D Experiments
naive B cell
1
E-TABM-702
native fetal RPE
1
E-GEOD-18811
primary CD34- mesenchymal stem cell
1
E-MEXP-66
leydig cell
1
E-MTAB-25
CD133-/alpha2 integrin low prostate epithelial cell
1
E-MEXP-993
naive T cell
1
E-GEOD-1460
31 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-4045, E-GEOD-1869, E-TABM-15, ... (28 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
colon carcinoma
2
E-MTAB-37, E-GEOD-3726
colorectal adenocarcinoma
2
E-MTAB-62, E-MTAB-37
serrated colorectal carcinoma
1
E-GEOD-4045
dysferlin mutation
1
E-GEOD-3307
lung large cell carcinoma
1
E-MTAB-62
99 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-GEOD-6907, E-GEOD-15205, E-GEOD-3183, ... (11 experiments)

Factor Value U/D Experiments
IL-13 (Homo sapiens)
1
E-GEOD-3183
TNF
1
E-GEOD-15205
no estradiol
1
E-GEOD-20081
vanadium pentoxide
1
E-GEOD-5339
not specified
1
E-GEOD-20081
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
20 more value(s).


Biosource provider

studied in E-MTAB-37, E-GEOD-14359

Factor Value U/D Experiments
Charite Universitätsmedizin Berlin
1
E-GEOD-14359
DSMZ
1
E-MTAB-37
Provitro GmbH, Berlin, Germany
1
E-GEOD-14359


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-22513, E-MEXP-1251

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-1561

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-108, E-MEXP-2340

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-GEOD-1045, E-GEOD-21750, E-GEOD-22593, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-22278, E-MEXP-1273, E-MEXP-2146

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653

Individual
studied in E-GEOD-2322, E-MTAB-197, E-TABM-176, E-GEOD-3284, E-MEXP-1243, ... (11 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108

Injury
studied in E-GEOD-19743

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Treatment
studied in E-GEOD-16837, E-GEOD-13818, E-GEOD-19815, E-GEOD-15799

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor size
studied in E-GEOD-6532

Processing time: 0.431 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM